CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $8.04B, above the global median of $1.15B
- PositionGross margin is 99.5%, higher than 95% of its Biotechnology peers (median 78%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.04BUSDvs all stocks (USD)
Revenue (TTM)
140.98MUSDvs all stocks (USD)
Beta
0.0770xvs all stocks
52-Week Change
186.57%vs all stocks
Market Capitalization
8.04BUSDvs all stocks (USD)
Enterprise Value
8.55BUSDvs all stocks (USD)
Forward P/E
124.17xvs Biotechnology peers
Price to Sales (TTM)
55.35xvs Biotechnology peers
Enterprise to Revenue
60.63xvs Biotechnology peers
Enterprise to EBITDA
-34.83xvs Biotechnology peers
Gross Margin
99.46%vs Biotechnology peers
Operating Margin
-157.88%vs Biotechnology peers
Return on Assets (TTM)
-34.38%vs Biotechnology peers
Revenue (TTM)
140.98MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1460USDUpdated Jul 19, 2026Quarterly Revenue Growth
167.60%vs Biotechnology peers
Gross Profit (TTM)
140.04MUSDvs all stocks (USD)
EBITDA (TTM)
-245.41MUSDvs all stocks (USD)
Net Income (TTM)
-854.53MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
167.64%vs Biotechnology peers
Operating Cash Flow (TTM)
-294.39MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-193.70MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
895.00KUSDFY2025 · Dec 31, 2025Revenue
113.29MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
753.00KUSDFY2025 · Dec 31, 2025Gross Profit
112.53MUSDFY2025 · Dec 31, 2025Operating Income
-256.03MUSDvs all stocks (USD)
Pre-tax Income
-351.61MUSDFY2025 · Dec 31, 2025Income Tax Expense
-135.00KUSDFY2025 · Dec 31, 2025Net Income
-351.47MUSDFY2025 · Dec 31, 2025EBIT
-239.08MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-282.76MUSDFY2025 · Dec 31, 2025Research & Development
218.56MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
150.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.69MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
112.53MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.3800USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.3800USDFY2025 · Dec 31, 2025Basic Shares Outstanding
919.86MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
919.86MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-351.47MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
74.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
-261.22MUSDFY2025 · Dec 31, 2025Free Cash Flow
-265.06MUSDDerived from operating cash flow minus capital expenditure. This filing charges 15.53M of depreciation against 3.85M of capital expenditure, and its own free-cash-flow line reads -309.19M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
89.43MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
71.32MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-351.47MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
15.53MUSDFY2025 · Dec 31, 2025Stock-based Compensation
36.81MUSDFY2025 · Dec 31, 2025Other Non-cash Items
90.58MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-40.21MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-190.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-12.26MUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.85MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-406.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-241.37MUSDFY2025 · Dec 31, 2025Sale of Investments
95.82MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-149.40MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-28.00KUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
2.88MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.13MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
402.29MUSDFY2025 · Dec 31, 2025Shares Outstanding
1.05BSharesUpdated Jul 19, 2026Float Shares
394.16MSharesUpdated Jul 19, 2026Shares Short
131.83MSharesUpdated Jul 19, 2026Short Ratio
9.91daysvs all stocks
Short % of Shares Outstanding
33.94%vs all stocks
% Held by Insiders
62.47%vs all stocks
% Held by Institutions
17.67%vs all stocks
Total Cash (MRQ)
380.88MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.3640USDUpdated Jul 19, 2026Total Debt (MRQ)
1.12BUSDvs all stocks (USD)
Current Ratio (MRQ)
6.67xvs Biotechnology peers
Book Value per Share (MRQ)
-0.8310USDUpdated Jul 19, 2026Total Assets
501.90MUSDvs all stocks (USD)
Total Current Assets
314.88MUSDFY2025 · Dec 31, 2025Total Liabilities
1.00BUSDFY2025 · Dec 31, 2025Total Non-current Assets
187.02MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
939.72MUSDFY2025 · Dec 31, 2025Total Current Liabilities
61.75MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
88.33MUSDFY2025 · Dec 31, 2025Other Short-term Investments
154.48MUSDFY2025 · Dec 31, 2025Accounts Receivable
42.57MUSDFY2025 · Dec 31, 2025Inventory
910.00KUSDFY2025 · Dec 31, 2025Accounts Payable
6.98MUSDFY2025 · Dec 31, 2025Short-term Debt
7.54MUSDFY2025 · Dec 31, 2025Other Current Liabilities
3.07MUSDFY2025 · Dec 31, 2025Long-term Debt
510.54MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
325.04MUSDFY2025 · Dec 31, 2025Common Stock (Book)
101.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-3.73BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-499.57MUSDvs all stocks (USD)
52-Week Low
1.95USDUpdated Jul 19, 202652-Week High
12.43USDUpdated Jul 19, 202652-Week Change
186.57%vs all stocks
Beta
0.0770xvs all stocks
50-Day MA
7.83USDUpdated Jul 19, 2026200-Day MA
5.65USDUpdated Jul 19, 2026Avg 10-Day Volume
10.50MSharesUpdated Jul 19, 2026Avg 30-Day Volume
12.22MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.8200USDUpdated Jul 19, 2026Other Income / Expense
14.26MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 99.5%, higher than 95% of its Biotechnology peers (median 78%)Significant
Gross margin: 0.99Industry median: 0.78Industry P95: 0.98Peers compared: 197
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.66
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $8.04B, above the global median of $1.15BNotable
Market cap (USD): 8,043,678,543Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Vaxcyte, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bio-Rad Laboratories Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
ALK-Abello A/S
Tier 1ProductionApproval-Gated PipelineRule
Immunovant Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Allist Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
InnoCare Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
TG Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Huadong Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alkermes plc
Tier 1ProductionApproval-Gated PipelineRule
Spyre Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Poet Technologies Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Procept BioRobotics Corporation
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Delcath Systems Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC